Up next

Autoplay

Overview of new combination therapies in acute myeloid leukemia (AML)

1 Views • 06/27/23
Share
Embed
administrator
administrator
Subscribers
0

At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, Naval Daver, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of new combination therapies involving hypomethylating agents. Dr Daver focuses on the following combinations: decitabine and vosarocin; decitabine and venetoclax (ABT-199); cytarabine and SGN-CD33A a CD33a monoclonal antibody .

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay